Erschienen in:
01.12.2001 | Adis New Drug Profile
Frovatriptan
A Viewpoint by Dr NT Mathew
verfasst von:
Dr N. T. Mathew
Erschienen in:
CNS Drugs
|
Ausgabe 12/2001
Einloggen, um Zugang zu erhalten
Excerpt
The most important basic consideration in modern therapy of migraine is that migraine pathophysiology, pharmacology and therapeutic response are different from those of nociceptive and neuropathic pain. Triptans, which are serotonin 5-HT1B/1D agonists, are migraine specific and are not useful in other types of pains. Triptans are well tested and have proven efficacy compared to nonspecific migraine therapy. They treat the entire spectrum of migraine symptomatology including nausea, vomiting, photophobia and phonophobia. On the whole, triptans are superior to non-triptans. …